FDA sets deadline to end sales of Ozempic, Wegovy copycats
Compounding pharmacies and telehealth companies selling lower-cost versions of Novo Nordisk's Ozempic and Wegovy will soon have to halt production after the FDA set deadlines to phase out compounded semaglutide.
Compounding pharmacies and telehealth companies selling lower-cost versions of Novo Nordisk's Ozempic and Wegovy will soon have to halt production after the FDA set deadlines to phase out compounded semaglutide.
